Nakamura Y, Yanagawa H
Department of Public Health, Jichi Medical School, Tochigi, Japan.
Eur J Pediatr. 1996 Apr;155(4):303-7. doi: 10.1007/BF02002717.
In spite of many reports of recurrent Kawasaki disease, little information about the risk factors associated with recurrence is available. We conducted a case-control study on 150 cases of recurrent Kawasaki disease and 1173 pair-matched controls selected from the database of nationwide surveys of the same disease in Japan. Items observed were: sex, age, use of intravenous gamma globulin, and cardiac sequelae at the first episode. Sex and cardiac sequelae did not affect the risk of recurrence. One- to 2-year-old children were more likely to be affected again than infants (odds ratio [OR] = 1.42; 95% confidence interval [CI], 0.94-2.13), and children who were 3 years of age or older were less likely to experience a recurrence than infants (OR = 0.59; 95% CI, 0.34-1.02). Intravenous gamma globulin therapy at the first episode increased the risk for recurrence of Kawasaki disease within 12 months (OR = 2.66, 95% CI, 1.06-6.66). However, it did not affect recurrences 12 months after the first episode (OR = 1.02; 95% CI, 0.53-1.97).
Patients with Kawasaki disease treated with intravenous gamma globulin are 2.66 times as likely to be affected by the disease again within 12 months as those treated without intravenous gamma globulin.
尽管有许多关于川崎病复发的报道，但关于复发相关危险因素的信息却很少。我们对150例川崎病复发患者和1173例配对对照进行了病例对照研究，这些对照选自日本全国同病调查数据库。观察的项目有：性别、年龄、静脉注射丙种球蛋白的使用情况以及首次发病时的心脏后遗症。性别和心脏后遗症不影响复发风险。1至2岁的儿童比婴儿更易再次发病（优势比[OR]=1.42；95%置信区间[CI]，0.94 - 2.13），3岁及以上儿童比婴儿复发的可能性小（OR = 0.59；95% CI，0.34 - 1.02）。首次发病时静脉注射丙种球蛋白治疗会增加12个月内川崎病复发的风险（OR = 2.66，95% CI，1.06 - 6.66）。然而，它对首次发病12个月后的复发没有影响（OR = 1.02；95% CI，0.53 - 1.97）。
接受静脉注射丙种球蛋白治疗的川崎病患者在12个月内再次患病的可能性是未接受静脉注射丙种球蛋白治疗患者的2.66倍。
